

**PATENT COOPERATION TREATY**

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:

**PCT**

**TRANSLATION**

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

(PCT Rule 43bis.1)

		Date of mailing (day/month/year)
Applicant's or agent's file reference <b>FP2728PCT</b>		<b>FOR FURTHER ACTION</b> See paragraph 2 below
International application No. <b>PCT/JP2005/000736</b>	International filing date (day/month/year) <b>21.01.2005</b>	Priority date (day/month/year) <b>21.01.2004</b>
International Patent Classification (IPC) or both national classification and IPC		
Applicant <b>KAO CORPORATION</b>		

1. This opinion contains indications relating to the following items:

<input checked="" type="checkbox"/>	Box No. I	Basis of the opinion
<input type="checkbox"/>	Box No. II	Priority
<input type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
<input type="checkbox"/>	Box No. IV	Lack of unity of invention
<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<input checked="" type="checkbox"/>	Box No. VI	Certain documents cited
<input type="checkbox"/>	Box No. VII	Certain defects in the international application
<input type="checkbox"/>	Box No. VIII	Certain observations on the international application

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/JP	Authorized officer
Facsimile No.	Telephone No.

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/JP2005/000736

Box No. I	Basis of this opinion
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item. <input type="checkbox"/> This opinion has been established on the basis of a translation from the original language into the following language _____, which is the language of a translation furnished for the purposes of international search (under Rule 12.3 and 23.1(b)).
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of: a. type of material <input type="checkbox"/> a sequence listing <input type="checkbox"/> table(s) related to the sequence listing b. format of material <input type="checkbox"/> in written format <input type="checkbox"/> in computer readable form c. time of filing/furnishing <input type="checkbox"/> contained in the international application as filed. <input type="checkbox"/> filed together with the international application in computer readable form. <input type="checkbox"/> furnished subsequently to this Authority for the purposes of search.
3.	<input type="checkbox"/> In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Additional comments:

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/JP2005/000736

Box No. V		Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																									
<p>1. Statement</p> <table> <tr> <td>Novelty (N)</td> <td>Claims</td> <td>1 - 3</td> <td>YES</td> </tr> <tr> <td></td> <td>Claims</td> <td></td> <td>NO</td> </tr> <tr> <td>Inventive step (IS)</td> <td>Claims</td> <td>1 - 3</td> <td>YES</td> </tr> <tr> <td></td> <td>Claims</td> <td></td> <td>NO</td> </tr> <tr> <td>Industrial applicability (IA)</td> <td>Claims</td> <td>1 - 3</td> <td>YES</td> </tr> <tr> <td></td> <td>Claims</td> <td></td> <td>NO</td> </tr> </table>				Novelty (N)	Claims	1 - 3	YES		Claims		NO	Inventive step (IS)	Claims	1 - 3	YES		Claims		NO	Industrial applicability (IA)	Claims	1 - 3	YES		Claims		NO
Novelty (N)	Claims	1 - 3	YES																								
	Claims		NO																								
Inventive step (IS)	Claims	1 - 3	YES																								
	Claims		NO																								
Industrial applicability (IA)	Claims	1 - 3	YES																								
	Claims		NO																								
<p>2. Citations and explanations:</p> <p>The following documents 1-3 are cited in the ISR.</p> <p>Document 1: JP, 2000-169358, A (Mikimoto Seiyaku Kabushiki Kaisha)      Document 2: JP, 9-40531, A (Kanebo, Ltd.)      Document 3: WO, 02/094212, A1 (L'OREAL)</p> <p>Document 1 describes that an eugenol glycoside shows a beautification effect.      Document 2 describes a hair tonic having an eugenol glycoside such as an eugenyl glycoside blended therein.</p> <p>However, any of the aforementioned documents does not mention a wrinkle diminishing effect of the eugenol glycoside such as an eugenyl glycoside.</p> <p>Document 3 discloses an eugenyl glycoside as any component which can be blended in a cosmetic agent effective against wrinkles, but the eugenyl glycoside is described as a group of 5<math>\alpha</math> reductase hindering components, and only symptoms associated with male hormones such as seborrhea and hirsutism are mentioned for the purpose of blending the components.</p> <p>Thus, the aforementioned documents do not deny that the subject matters of claims of this application appear to be novel and to involve an inventive step.</p>																											

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/JP2005/000736

Box No. VI	Certain documents cited			
1.	Certain published documents (Rule 43bis.1 and 70.10)			
	Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
	JP 2004-107250 A (PA)	08.04.2004	18.09.2002	
2.	Non-written disclosures (Rule 43bis.1 and 70.9)			
	Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non-written disclosure (day/month/year)	